JP2020522543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522543A5 JP2020522543A5 JP2019567598A JP2019567598A JP2020522543A5 JP 2020522543 A5 JP2020522543 A5 JP 2020522543A5 JP 2019567598 A JP2019567598 A JP 2019567598A JP 2019567598 A JP2019567598 A JP 2019567598A JP 2020522543 A5 JP2020522543 A5 JP 2020522543A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- motomeko
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127275A JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516489P | 2017-06-07 | 2017-06-07 | |
| US62/516,489 | 2017-06-07 | ||
| US201862614801P | 2018-01-08 | 2018-01-08 | |
| US62/614,801 | 2018-01-08 | ||
| PCT/EP2018/065071 WO2018224609A1 (en) | 2017-06-07 | 2018-06-07 | Therapeutic antibodies based on mutated igg hexamers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127275A Division JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522543A JP2020522543A (ja) | 2020-07-30 |
| JP2020522543A5 true JP2020522543A5 (https=) | 2021-07-26 |
Family
ID=62636167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567598A Pending JP2020522543A (ja) | 2017-06-07 | 2018-06-07 | 変異ＩｇＧ六量体に基づく治療用抗体 |
| JP2023127275A Withdrawn JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127275A Withdrawn JP2023145720A (ja) | 2017-06-07 | 2023-08-03 | 変異ＩｇＧ六量体に基づく治療用抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200247897A1 (https=) |
| EP (1) | EP3635005A1 (https=) |
| JP (2) | JP2020522543A (https=) |
| KR (1) | KR20200027944A (https=) |
| CN (1) | CN111328335A (https=) |
| BR (1) | BR112019025328A2 (https=) |
| MA (1) | MA49259A (https=) |
| MX (1) | MX2019014407A (https=) |
| TW (1) | TW201919692A (https=) |
| WO (1) | WO2018224609A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3580233A1 (en) | 2017-02-10 | 2019-12-18 | Genmab B.V. | Polypeptide variants and uses thereof |
| MX2020011552A (es) | 2018-05-03 | 2020-11-24 | Genmab Bv | Combinaciones de variantes de anticuerpos y usos de las mismas. |
| US20220315661A1 (en) * | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| US20230272105A1 (en) * | 2020-01-16 | 2023-08-31 | Genmab A/S | Formulations of cd38 antibodies and uses thereof |
| JP2023534726A (ja) * | 2020-07-23 | 2023-08-10 | ジェンマブ ビー．ブイ． | 多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用 |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| WO2000046147A2 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2010003766A2 (en) | 2008-06-17 | 2010-01-14 | Apogenix Gmbh | Multimeric tnf receptors |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US20120070432A1 (en) | 2009-05-28 | 2012-03-22 | Amgen Inc. | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CN102654260B (zh) | 2011-09-29 | 2014-09-03 | 北京京东方光电科技有限公司 | 一种背光源和液晶显示器 |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| CN109476737A (zh) * | 2015-12-01 | 2019-03-15 | 根马布有限公司 | 抗dr5抗体及其使用方法 |
-
2018
- 2018-06-07 EP EP18731987.6A patent/EP3635005A1/en active Pending
- 2018-06-07 MA MA049259A patent/MA49259A/fr unknown
- 2018-06-07 MX MX2019014407A patent/MX2019014407A/es unknown
- 2018-06-07 TW TW107119651A patent/TW201919692A/zh unknown
- 2018-06-07 KR KR1020207000017A patent/KR20200027944A/ko not_active Ceased
- 2018-06-07 US US16/618,722 patent/US20200247897A1/en not_active Abandoned
- 2018-06-07 BR BR112019025328-9A patent/BR112019025328A2/pt not_active Application Discontinuation
- 2018-06-07 CN CN201880050867.4A patent/CN111328335A/zh active Pending
- 2018-06-07 JP JP2019567598A patent/JP2020522543A/ja active Pending
- 2018-06-07 WO PCT/EP2018/065071 patent/WO2018224609A1/en not_active Ceased
-
2023
- 2023-08-03 JP JP2023127275A patent/JP2023145720A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522543A5 (https=) | ||
| US11103579B2 (en) | Combination of DR5 agonist and anti-PD-1 antagonist and methods of use | |
| JP2019500869A5 (https=) | ||
| JP7126941B2 (ja) | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| JP2019501151A5 (https=) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| JP2021515566A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| CN113825527A (zh) | 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合 | |
| JP7548924B2 (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| ES2951864T3 (es) | Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama | |
| RU2836467C2 (ru) | Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований | |
| KR102956075B1 (ko) | 암을 치료하기 위한 항-pd-1 항체와 이특이적 항-cd20/항-cd3 항체의 조합 | |
| CN121175334A (zh) | 在治疗癌症中的使用pd-l1抑制剂的新辅助免疫疗法 | |
| CA3009161C (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
| CN116615238A (zh) | 用于治疗癌症和减轻细胞因子释放综合征的抗体组合 | |
| CN120152716A (zh) | 包括抗cd19抗体和ezh2调节剂的治疗 | |
| RU2023110743A (ru) | Биспецифические антитела к pd-1/cd40 и их применение | |
| NZ743316A (en) | Anti-dr5 antibodies and methods of use thereof | |
| RU2019128199A (ru) | 1-(4-амино-5-бром-6-(1h-пиразол-1-ил)пиримидин-2-ил)-1h-пиразол-4-ол и его применение в лечении рака | |
| NZ743316B2 (en) | Anti-dr5 antibodies and methods of use thereof | |
| EA042623B1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли |